• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjpharmLink to Publisher's site
Br J Pharmacol. Feb 1983; 78(2): 287–292.
PMCID: PMC2044703

Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues.


1--Platelet-rich plasma (PRP) from humans, cats, dogs (after addition of 10 microM adrenaline), rabbits and guinea-pigs aggregated in response to sodium arachidonate or 9,11-azo-prostaglandin H2, while PRP obtained from sheep was unresponsive to either agent. 2--The stable thromboxane (Tx) analogues, carbocyclic TxA2 (CTA2) and pinane TxA2 (PTA2) significantly inhibited these aggregatory responses in platelets from humans, dogs and guinea-pigs, while PTA2 but not CTA2 produced significant inhibition in cat platelets. The aggregatory response of PRP from rabbits was not significantly blocked by either analogue. 3--CTA2 and the endoperoxide analogue 9,11-methanoepoxy PGH2 (U-46619) constricted coronary arteries from cats, dogs, rabbits and guinea-pigs, while sheep vessels were unresponsive to either analogue. 4--Vasoconstrictor responses to U-46619 were significantly attenuated by PTA2 in vessels from all species. However, constriction produced by CTA2 was blocked significantly only in vessels from cats, dogs and guinea-pigs. 5--These results demonstrate the species differences which exist in the responsiveness of platelets and coronary arteries to thromboxane and endoperoxide analogues. Furthermore, the results illustrate the importance of species selection in the study of thromboxane antagonists for potential therapeutic use.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1006K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Coleman RA, Humphrey PP, Kennedy I, Levy GP, Lumley P. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol. 1981 Jul;73(3):773–778. [PMC free article] [PubMed]
  • Corey EJ, Nicolaou KC, Machida Y, Malmsten CL, Samuelsson B. Synthesis and biological properties of a 9,11-azo-prostanoid: highly active biochemical mimic of prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3355–3358. [PMC free article] [PubMed]
  • Ingerman-Wojenski C, Silver MJ, Smith JB, Macarak E. Bovine endothelial cells in culture produce thromboxane as well as prostacyclin. J Clin Invest. 1981 May;67(5):1292–1296. [PMC free article] [PubMed]
  • Lefer AM, Smith EF, 3rd, Araki H, Smith JB, Aharony D, Claremon DA, Magolda RL, Nicolaou KC. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1706–1710. [PMC free article] [PubMed]
  • Lewy RI, Smith JB, Silver MJ, Saia J, Walinsky P, Wiener L. Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal's angina. Prostaglandins Med. 1979 Apr;2(4):243–248. [PubMed]
  • Meyers KM, Katz JB, Clemmons RM, Smith JB, Holmsen H. An evaluation of the arachidonate pathway of platelets from companion and food-producing animals, mink, and man. Thromb Res. 1980 Oct 1;20(1):13–24. [PubMed]
  • Morooka S, Kobayashi M, Takahashi T, Takashima Y, Sakamoto M, Shimamoto T. Experimental ischemic heart disease--effects of synthetic thromboxane A2. Exp Mol Pathol. 1979 Jun;30(3):449–457. [PubMed]
  • Mustard JF, Packham MA. Factors influencing platelet function: adhesion, release, and aggregation. Pharmacol Rev. 1970 Jun;22(2):97–187. [PubMed]
  • Namm DH, Tadepalli AS, High JA. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. Thromb Res. 1982 Feb 15;25(4):341–350. [PubMed]
  • Nicolaou KC, Magolda RL, Smith JB, Aharony D, Smith EF, Lefer AM. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2566–2570. [PMC free article] [PubMed]
  • Salzman PM, Salmon JA, Moncada S. Prostacyclin and thromboxane A2 synthesis by rabbit pulmonary artery. J Pharmacol Exp Ther. 1980 Oct;215(1):240–247. [PubMed]
  • Smith EF, 3rd, Lefer AM, Aharony D, Smith JB, Magolda RL, Claremon D, Nicolaou KC. Carbocyclic thromboxane A2: aggrevation of myocardial ischemia by a new synthetic thromboxane A2 analog. Prostaglandins. 1981 Mar;21(3):443–456. [PubMed]
  • Smith JB, Araki H, Lefer AM. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation. 1980 Dec;62(6 Pt 2):V19–V25. [PubMed]
  • Smith JB, Silver MJ, Ingerman CM, Kocsis JJ. Prostaglandin D2 inhibits the aggregation of human platelets. Thromb Res. 1974 Sep;5(3):291–299. [PubMed]
  • Thomas DP, Niewiarowski S, Ream VJ. Release of adenine nucleotides and platelet factor 4 from platelets of man and four other species. J Lab Clin Med. 1970 Apr;75(4):607–618. [PubMed]
  • Wang HH, Kulkarni PS, Eakins KE. Effects of prostaglandins and thromboxane A2 on the coronary circulation of adult dogs and puppies. Eur J Pharmacol. 1980 Aug 22;66(1):31–41. [PubMed]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...